EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

OCIAD2 as a novel prognostic and therapeutic biomarker for pancreatic cancer: A study based on transcriptomic signature and bioinformatics analysis

Zhongyuan Cui iD, Xia Lei, Yani Gou, Zhixian Wu iD, Xiaojun Huang

PLOS Computational Biology · 07.10.2025 · 21 (10) · e1013566

DOI: 10.1371/journal.pcbi.1013566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 07.10.2025. Verfasst von Zhongyuan Cui und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gansu Provincial Food and Drug Administration, Science and Technology Innovation Joint Fund Project of Fujian Province, Cuiying Science and Technology Innovation Program of the Second Hospital of Lanzhou University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

It is urgent to explore the potential biomarkers for pancreatic cancer (PC) prognosis and treatment to improve patients’ outcomes.

Methods

Firstly, we performed an integrated bioinformatics analysis based on extensive transcriptome data from 615 PC tumors and 329 adjacent tissues, screening for genes with prognostic value. We then validated the prognostic value of OCIAD2 , DCBLD2 , and SAMD9 in different datasets and analyzed their expression levels in single-cell sequencing datasets of normal, paracancer, primary, and metastatic tissues. Next, we further explored the carcinogenic effect after knocking down the expression of OCIAD2 in PC cancer cell line. Finally, a drug sensitivity analysis was conducted.

Results

Differentially expressed genes (DEGs) analysis identified 22 DEGs: ACSL5 , ANTXR1 , AP1S3 , ATP2C2 , B3GNT5 , C15orf48 , CAPG , CTSK , DAPP1 , DCBLD2 , GPX8 , HEPH , IFI44 , KRT23 , NCF2 , OCIAD2 , SAMD9 , SLC39A10 , ST6GALNAC1 , TBC1D2 , TMSB10 and TSPAN5 with prognostic value in PC, though the related function and mechanism are still unclear. Single-cell sequencing results indicated that OCIAD2 was prominently expressed in ductal cells of primary and metastatic tumors. The expression levels of OCIAD2 mRNA and protein were the highest in pancreatic tumor tissues. Mechanism studies revealed that STAT1 and STAT2 in the JAK-STAT pathway and CCND1 , CDK1, and CDK2 in the cell cycle pathway were significantly down-regulated after OCIAD2 knockdown. Drug sensitivity analysis identified 25 compounds significantly associated with OCIAD2 .

Conclusions

These results indicate that OCIAD2 is a potential prognostic biomarker and therapeutic target for PC patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsBiomarkers, TumorHumansComputational BiologyPrognosisCell Line, TumorGene Expression Regulation, NeoplasticTranscriptomeGene Expression ProfilingMale

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Gastroenterology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, China.
  • Department of Hepatobiliary Disease, 900th Hospital of the Joint Logistics Support Force (Dongfang Hospital of Xiamen University, School of Medicine, Xiamen University), Fuzhou, Fujian, China.

ORCID-Profile: Zhongyuan Cui, Zhixian Wu

Förderung

  • Gansu Provincial Food and Drug Administration
  • Science and Technology Innovation Joint Fund Project of Fujian Province
  • Cuiying Science and Technology Innovation Program of the Second Hospital of Lanzhou University
  • 2022 Drug Supervision Scientific Project of Gansu Provincial Food and Drug Administration

Zitieren

APA

Cui, Z., Lei, X., Gou, Y., Wu, Z., & Huang, X. (2025). OCIAD2 as a novel prognostic and therapeutic biomarker for pancreatic cancer: A study based on transcriptomic signature and bioinformatics analysis. PLOS Computational Biology, 21(10), e1013566. https://doi.org/10.1371/journal.pcbi.1013566

Vancouver

Cui Z, Lei X, Gou Y, Wu Z, Huang X. OCIAD2 as a novel prognostic and therapeutic biomarker for pancreatic cancer: A study based on transcriptomic signature and bioinformatics analysis. PLOS Computational Biology. 2025;21(10):e1013566. doi:10.1371/journal.pcbi.1013566

BibTeX
@article{Cui2025,
  author = {Cui, Zhongyuan and Lei, Xia and Gou, Yani and Wu, Zhixian and Huang, Xiaojun},
  title = {OCIAD2 as a novel prognostic and therapeutic biomarker for pancreatic cancer: A study based on transcriptomic signature and bioinformatics analysis},
  journal = {PLOS Computational Biology},
  year = {2025},
  volume = {21},
  number = {10},
  pages = {e1013566},
  doi = {10.1371/journal.pcbi.1013566}
}
Kostenlos starten →